Your browser is no longer supported. Please, upgrade your browser.
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E235.39 EPS (ttm)1.08 Insider Own18.10% Shs Outstand76.02M Perf Week16.71%
Market Cap19.33B Forward P/E63.38 EPS next Y4.01 Insider Trans-0.30% Shs Float61.74M Perf Month57.68%
Income86.10M PEG1471.18 EPS next Q0.13 Inst Own76.70% Short Float8.66% Perf Quarter82.31%
Sales729.70M P/S26.48 EPS this Y26.40% Inst Trans1.29% Short Ratio4.50 Perf Half Y106.77%
Book/sh10.95 P/B23.22 EPS next Y475.47% ROA9.60% Target Price194.58 Perf Year81.24%
Cash/sh11.27 P/C22.55 EPS next 5Y0.16% ROE12.00% 52W Range82.51 - 232.40 Perf YTD107.93%
Dividend- P/FCF120.34 EPS past 5Y40.90% ROI10.40% 52W High9.39% Beta0.72
Dividend %- Quick Ratio5.10 Sales past 5Y139.30% Gross Margin94.50% 52W Low208.11% ATR11.40
Employees607 Current Ratio5.20 Sales Q/Q134.80% Oper. Margin47.70% RSI (14)88.37 Volatility4.18% 5.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.20% Profit Margin11.80% Rel Volume15.75 Prev Close230.48
ShortableYes LT Debt/Eq0.00 EarningsFeb 18 AMC Payout0.00% Avg Volume1.19M Price254.22
Recom2.20 SMA2037.64% SMA5060.67% SMA200102.18% Volume18,698,087 Change10.30%
Mar-05-15Reiterated RBC Capital Mkts Sector Perform $145 → $261
Feb-26-15Downgrade WallachBeth Buy → Hold $228
Feb-19-15Reiterated Deutsche Bank Buy $180 → $205
Feb-19-15Downgrade ROTH Capital Buy → Neutral $189 → $187
Jan-29-15Reiterated ROTH Capital Buy $188 → $189
Oct-17-14Reiterated ROTH Capital Buy $185 → $188
Oct-14-14Reiterated ROTH Capital Buy $183 → $185
Aug-01-14Upgrade WallachBeth Hold → Buy
May-27-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
May-05-14Reiterated RBC Capital Mkts Outperform $150 → $110
Feb-21-14Reiterated Deutsche Bank Buy $170 → $180
Dec-18-13Initiated WallachBeth Hold $108
Sep-26-13Initiated Deutsche Bank Buy $170
Dec-12-12Reiterated Wedbush Outperform $93 → $110
Aug-24-12Initiated Stifel Nicolaus Hold
Aug-02-12Downgrade Needham Buy → Hold
May-17-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
May-17-12Reiterated Needham Buy $23 → $32
Feb-21-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
Dec-09-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
Mar-05-15 09:49PM  AbbVies Expensive Growth Tonic at The Wall Street Journal +10.30%
09:47PM  Biotech Bidding War Yields Rich Price at The Wall Street Journal
08:25PM  Bidding War Yields Rich Price for Biotech at The Wall Street Journal
08:00PM  Harwood Feffer LLP Announces Investigation of Pharmacyclics, Inc. PR Newswire
07:25PM  Biz Break: Pharmacyclics cofounder on $21B buyout -- 'This is a company that kept fighting' at San Jose Mercury News
06:57PM  [video] Bored by Golf and Cancer Cured, AbbVie CEO Came Back to Work Bloomberg
06:55PM  Billionaire Robert Duggan's Bet On Pharmacyclics Stands Among Top Trades Of Crisis Era at Forbes
06:42PM  Bored by Golf and Cured of Cancer, AbbVie CEO Came Back for More at Bloomberg
06:32PM  Medical Stocks Highlight The Day's New Highs at Investor's Business Daily
06:32PM  Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally at Investor's Business Daily
06:32PM  Expect More M&A Activity In Red-Hot Biotech Group at Investor's Business Daily
06:24PM  The $42 Billion Drug? Why AbbVie May Have Overpaid for Pharmacyclics at The Wall Street Journal
06:13PM  Cramer: This X factor is ignored in your portfolio at CNBC
06:09PM  Inside the $21 Billion War for a Blockbuster Cancer Drug Bloomberg
06:04PM  Nasdaq stocks posting largest volume increases AP
05:51PM  AbbVie, Pharmacyclics: A Winning $21 Billion Deal at Barrons.com
05:48PM  AbbVie wins Pharmacyclics in $21B deal at USA TODAY
05:44PM  AbbVie to buy leukemia drug maker Pharmacyclics for $21 billion at Los Angeles Times
05:35PM  Pharmacyclics, Inc. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
05:23PM  AbbVie CEO defends Pharmacyclics deal to skeptical investors Reuters
04:56PM  AbbVie Stock Slides On Pricey Pharmacyclics Deal at Investor's Business Daily
04:48PM  Analysts Mixed On Premium For Pharmacyclics Benzinga
04:42PM  Stocks close higher; Europe gains as ECB unveils stimulus at Los Angeles Times
04:40PM  AbbVie (ABBV) Stock Declines In Trading Today Following $21B Pharmacyclics Purchase at TheStreet
04:35PM  AbbVie and Costco are big market movers AP
04:34PM  U.S. stocks eke out gains in choppy session ahead of jobs report at MarketWatch
04:28PM  US STOCKS-Wall St closes up slightly ahead of jobs report Reuters
04:24PM  Stocks Rise From Pullback; Pharmacyclics Jumps On Buyout News at Investor's Business Daily
04:23PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Pharmacyclics Inc. Concerning its Proposed Sale to AbbVie Inc. PCYC Business Wire
04:15PM  AbbVies Bid Ups Ante as Buyers Bet on Cancer Drugs: Real M&A at Bloomberg
04:10PM  Stocks End Slightly Higher Morningstar
03:37PM  AbbVie joins the pharma chain reaction at Financial Times
03:15PM  US STOCKS-Wall St up slightly ahead of jobs report Reuters
03:00PM  Stocks Turn Positive; Embraer Falls On Weak Earnings at Investor's Business Daily
02:50PM  AbbVie's Expensive Growth Tonic at The Wall Street Journal
02:32PM  AbbVie wins three-way fight over Pharmacyclics at Financial Times
02:15PM  AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal Reuters
02:07PM  AbbVie boosts cancer drug pipeline with $21 bln Pharmacyclics deal Reuters
01:17PM  AbbVie to buy leukemia drugmaker Pharmacyclics for $21B AP
12:46PM  Why AbbVie's Stock Is Selling Off After Its $21 Billion Deal at The Wall Street Journal
12:46PM  AbbVie in $21 Billion Biotech Deal at The Wall Street Journal
12:31PM  Pharmacyclics CEO sees stake value soar at Financial Times
12:23PM  AbbVie snags Pharmacyclics -- and its star drug Imbruvica -- for $21B (Video) at bizjournals.com
12:14PM  Primecap Odyssey Outperforms on 40-Fold Gain in Pharmacyclics at Bloomberg
12:14PM  Centerview builds record on pharma deals at Financial Times
12:03PM  Stocks Higher At Noon; Costco, Middleby Rebound at Investor's Business Daily
11:48AM  AbbVie buying Pharmacyclics for $21B CNBC
11:30AM  AbbVie's $21B Pharmacyclics Buy A Red Flag For Deal-Crazy Sector at Forbes
11:29AM  US STOCKS-Wall St little changed after 2-day drop, data Reuters
11:25AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie -- PCYC Business Wire
11:21AM  Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Funds Other Top Picks at Insider Monkey
11:15AM  Sunnyvale's Pharmacyclics sells for $21 billion to AbbVie at San Jose Mercury News
11:13AM  Three reasons why AbbVie bought Sunnyvale's Pharmacyclics for $21B at bizjournals.com
11:12AM  AbbVie Emerges With $21 Billion Deal in Fight to the Very End at Bloomberg
11:03AM  Pharmacyclics: Johnson & Johnson Would Have Made Way More Sense at Barrons.com
10:56AM  Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal at TheStreet
10:47AM  AbbVie to Acquire Pharmacyclics: What Wall Street's Saying at TheStreet
10:29AM  Pharmacyclics shares soar on AbbVie deal at MarketWatch
10:23AM  Kroger gains on higher profit; AbbVie slides on merger news at MarketWatch
10:10AM  Company News for March 05, 2015 - Corporate Summary Zacks
10:02AM  US stocks open higher; Pharmacyclics jumps on AbbVie bid AP
09:50AM  On the ECB & China's Growth - Ahead of Wall Street Zacks
09:15AM  US STOCKS-Wall St to open slightly higher after 2-day fall Reuters
09:11AM  Stock Futures Climb Toward Open; AbbVie Bid Boosts Pharmacyclics at Investor's Business Daily
09:04AM  Mark Cuban: This tech bubble is far worse than back in 2000 at MarketWatch
09:01AM  Big drug deal; Costco gets tax boost; H&R Block loses business Yahoo Finance
08:49AM  Abbvie/Pharmacyclics: pay to play at Financial Times
08:30AM  AbbVie buys Pharmacyclics in $21B deal CNBC
08:04AM  ECB unveils bond buying details; $21B drug deal; Apple's achilles' heel? Yahoo Finance
07:50AM  Early movers: PCYC, COST, DNKN, MCD, AAPL & more at CNBC
07:44AM  US STOCKS-Futures climb after 2-day fall; initial claims on tap Reuters
06:56AM  AbbVie Makes Cancer Therapy Push Bloomberg
06:38AM  AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug at TheStreet
05:49AM  Q&A - why Abbvie had to strike $21bn Pharmacyclics deal at Financial Times
01:35AM  AbbVie trumps J&J in deal for cancer drugmaker at Financial Times
12:49AM  AbbVie Will Buy Pharmacyclics For $21 Billion at Investor's Business Daily
Mar-04-15 11:16PM  Abbvie To Pay $21 Billion For Cancer Biotech Pharmacyclics at Forbes +6.33%
10:59PM  AbbVie to buy Pharmacyclics in $21 billion deal Reuters
06:27PM  J&J nearing deal to buy cancer drug maker Pharmacyclics - FT Reuters
06:24PM  Report: J&J close to deal to buy partner Pharmacyclics AP
05:48PM  Biz Break: Pharmacyclics to sell in biggest biotech deal of the year, reports say at San Jose Mercury News
05:23PM  J&J Said to Agree to Acquire Pharmacyclics for Cancer Drug at Bloomberg
05:20PM  After-hours buzz: Vivint, H&R Block, Encana & more at CNBC
04:33PM  Johnson & Johnson near deal for Pharmacyclics: FT at MarketWatch
Mar-03-15 03:33PM  Leerink: Pharmacyclics Is Now Worth $240 Benzinga
Mar-02-15 06:44PM  Big Cap 20 Reflecting Market Leadership at Investor's Business Daily
Feb-27-15 02:45PM  Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases PR Newswire
02:30PM  In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody PR Newswire
11:31AM  Cramer: Pharmacyclics-Johnson & Johnson Deal Unlikely at This Price at TheStreet
09:52AM  Cramer's Stop Trading: PCYC CNBC
09:30AM  The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Zacks
Feb-26-15 11:10AM  Biotech Making A Comeback - Here Is One Stock to Watch Company Spotlight
11:08AM  6 reasons biotech stocks may soon tank at MarketWatch
11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Zacks
10:08AM  Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors Benzinga
09:30AM  Familiar ETF Friend Will Enjoy a Pharmacyclics Sale ETF Trends
09:00AM  Pharmacyclics (PCYC) Jumps 16.9% on Takeover Rumors - Analyst Blog Zacks
06:54AM  Pharmacyclics downgraded by WallachBeth Briefing.com
Feb-25-15 09:07PM  Cancer Drug Once Bought for $7 Million May Now Fetch $18 Billion Bloomberg +16.86%
06:51PM  Pharmacyclics said to weigh sale of U.S. cancer drugmaker at San Jose Mercury News
Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenstrm's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company's product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics, Inc. has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghChief Financial OfficerNov 13Option Exercise61.601,00061,60039,611Nov 17 04:19 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Option Exercise6.843,00020,5206,193Nov 17 04:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 13Sale141.303,000423,9023,193Nov 17 04:30 PM
Soni Manmeet SinghChief Financial OfficerNov 13Sale141.441,000141,44238,611Nov 17 04:19 PM
Zanganeh MakyChief Operating OfficerNov 12Option Exercise7.195,93142,644216,243Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 12Sale137.965,931818,216210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Option Exercise32.381,50048,5701,705Nov 10 06:30 PM
Zanganeh MakyChief Operating OfficerNov 10Option Exercise2.3023,00052,900233,312Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 10Sale133.8323,0003,078,027210,312Nov 12 06:07 PM
Love Richard BGeneral CounselNov 10Sale133.871,500200,805205Nov 10 06:30 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Option Exercise6.845,00034,2008,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerNov 07Option Exercise2.301,5513,567211,863Nov 12 06:07 PM
Zanganeh MakyChief Operating OfficerNov 07Sale135.011,551209,401210,312Nov 12 06:07 PM
Fardis MariaChief of Oncology Ops & AllianNov 07Sale134.505,000672,5003,193Nov 10 06:28 PM
Zanganeh MakyChief Operating OfficerSep 04Option Exercise2.305,00011,500215,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 04Sale122.005,000610,000210,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Option Exercise2.307,00016,100217,311Sep 04 05:54 PM
Zanganeh MakyChief Operating OfficerSep 03Sale121.577,000850,980210,311Sep 04 05:54 PM
Love Richard BGeneral CounselAug 27Option Exercise32.381,50048,5701,704Aug 28 09:52 PM
Love Richard BGeneral CounselAug 27Sale124.001,500186,000204Aug 28 09:52 PM
Tan HeowChief Quality&Tech OperationsAug 21Option Exercise27.052,19659,4024,069Aug 22 02:45 PM
Tan HeowChief Quality&Tech OperationsAug 13Option Exercise27.0510,000270,50011,873Aug 13 05:27 PM
Tan HeowChief Quality&Tech OperationsAug 13Sale123.5810,0001,235,8081,873Aug 13 05:27 PM
McGreivy JesseChief Medical OfficerAug 07Option Exercise73.0934,0622,489,51534,062Aug 07 06:51 PM
McGreivy JesseChief Medical OfficerAug 07Sale120.9234,0624,118,6100Aug 07 06:51 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM